Pharmaceutical developer Merck announced Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for WELIREG in combination with lenvatinib. The regulatory opinion supports approval for adult patients with advanced clear cell renal cell carcinoma whose disease progressed following systemic anti-PD-1 or anti-PD-L1 immunotherapy. The European Commission will evaluate the recommendation to issue a legally binding licensing decision within sixty days.
Clear cell renal cell carcinoma accounts for roughly eighty percent of all diagnosed renal malignancies across European healthcare systems; despite significant advances in frontline immunotherapy regimens, patients who develop resistance face poor clinical prognoses and constrained secondary options.
According to Merck's official corporate newsroom statement and oncology analysis in Urology Times on Friday, the positive CHMP recommendation was backed by robust Phase 3 trial data. Outlining the regulatory development, the official announcement stated: "Merck Receives Positive EU CHMP Opinion for WELIREG (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component following treatment with an anti-PD-1/PD-L1 therapy." The clinical study demonstrated that the combination therapy generated a statistically significant twenty-six percent reduction in the risk of disease progression or mortality compared with standard tyrosine kinase inhibitor monotherapy.
Safety profiles observed during the multinational trial remained consistent with previous monotherapy evaluations. Commonly documented adverse events included manageable anemia, fatigue, and elevated blood pressure, which oncologists successfully addressed with standard dose modification protocols. No novel cumulative toxicities were identified during trial tracking. WELIREG operates as a first-in-class oral hypoxia-inducible factor-2 alpha inhibitor that disrupts cancer cell vascularization and tumor proliferation pathways. A final clearance from the European Commission will grant centralized marketing authorization across all twenty-seven European Union member nations, alongside Norway, Iceland, and Liechtenstein. National reimbursement agencies will commence formal cost-effectiveness reviews early next year.
